7MM regulatory T-cell market to grow over 57% CAGR by 2034

Currently, no Treg-based therapies are approved.

The regulatory T-cells (Tregs) sector across the seven major markets (7MM) is projected to grow at a compound annual growth rate exceeding 57% through 2034, according to a report by DelveInsight.

The market is expected to expand as companies actively develop new regulatory T-cell therapies to address different conditions such as Lupus Nephritis, Atopic Dermatitis, Rheumatoid Arthritis, and Psoriasis.

Currently, no Treg-based therapies are approved. The first approval is anticipated in the US by 2026, which is expected to drive early market expansion.

7MM = US, Germany, France, Italy, Spain, UK, and Japan.